This was the stock's second consecutive day of gains.

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has experienced a notable downturn, touching a 52-week low of $666. With a ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...